Compare FUTU & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUTU | ZBH |
|---|---|---|
| Founded | 2011 | 1927 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 18.7B |
| IPO Year | 2019 | N/A |
| Metric | FUTU | ZBH |
|---|---|---|
| Price | $180.22 | $95.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 20 |
| Target Price | ★ $208.60 | $107.84 |
| AVG Volume (30 Days) | 982.5K | ★ 2.0M |
| Earning Date | 11-18-2025 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.04% |
| EPS Growth | ★ 119.17 | N/A |
| EPS | ★ 8.95 | 4.03 |
| Revenue | $2,442,834,991.00 | ★ $8,010,900,000.00 |
| Revenue This Year | $85.62 | $7.98 |
| Revenue Next Year | $14.24 | $5.21 |
| P/E Ratio | ★ $20.24 | $22.97 |
| Revenue Growth | ★ 87.15 | 5.47 |
| 52 Week Low | $70.60 | $85.33 |
| 52 Week High | $202.53 | $114.44 |
| Indicator | FUTU | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 61.75 |
| Support Level | $164.20 | $89.50 |
| Resistance Level | $168.22 | $91.99 |
| Average True Range (ATR) | 4.68 | 1.79 |
| MACD | 2.05 | 0.49 |
| Stochastic Oscillator | 72.53 | 98.75 |
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.